Retension Pharmaceuticals

Private

Clinical-stage biopharmaceutical company developing tissue-targeted PDE5 inhibitor RTN-001 for uncontrolled and resistant hypertension and other serious cardiovascular conditions.

Company Info

Sector:Biotechnology / Small Molecule Pharma

Headquarters:Falls Church, Virginia, USA

Founded:2023

Website:www.retensionpharmaceuticals.com/

Funding Round:Series A

Total Funding:$22.7M

Clinical Development Pipeline

RTN-001

Target: Tissue-targeted PDE5 inhibitor

Uncontrolled and resistant hypertension

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

Eric Keller

Co-Founder and Chief Executive Officer

Paul Sweetnam

Co-Founder

Careers & Job Openings

See all open roles

Careers

Falls Church, Virginia, USA

Apply Now →

Retension Pharmaceuticals

Company Info

Clinical Development Pipeline

RTN-001

Recent News